No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TYRA TYRA BIOSCIENCES, INC.
- 16.700
- -0.580-3.36%
Close Jul 2 16:00 ET
- 16.710
- +0.010+0.06%
Post 19:30 ET
877.41MMarket Cap-9881P/E (TTM)
18.110High16.690Low127.71KVolume17.230Open17.280Pre Close2.20MTurnover0.80%Turnover RatioLossP/E (Static)52.54MShares21.14052wk High2.25P/B267.24MFloat Cap10.38052wk Low--Dividend TTM16.00MShs Float31.360Historical High--Div YieldTTM8.22%Amplitude4.930Historical Low17.260Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Tyra Biosciences Plans to Develop Potential Treatment of Dwarfism, File Application in H2
Tyra Biosciences (TYRA) said Tuesday it plans to develop TYRA-300 for the potential treatment of hypochondroplasia following encouraging results in the preclinical proof-of-concept study. The company
Express News | Tyra Biosciences Announces Preclinical Proof-Of-Concept Results With TYRA-300; Demonstrates Increases In Long Bone Length And Binding Against HCH Altered Protein; Remains On Track To Submit ACH Investigational New Drug Application In 2H24
Express News | Tyra Biosciences Inc: Remains on Track to Submit Ach Investigational New Drug Application in 2H24
Express News | Tyra Biosciences Announces Preclinical Proof-of-Concept Results With Tyra-300 in Hypochondroplasia (Hch)
Does This Valuation Of Tyra Biosciences, Inc. (NASDAQ:TYRA) Imply Investors Are Overpaying?
TYRA BIOSCIENCES, INC.(TYRA.US) Officer Sells US$74,044.9 in Common Stock
$TYRA BIOSCIENCES, INC.(TYRA.US)$ Officer Bensen Daniel sold 3,702 shares of common stock on Jun 7, 10, 2024 at an average price of $20.0013 for a total value of $74,044.9.Source: Announcement What is
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
Upgrades
• $Funko(FNKO.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $28 (from $25)
• $Southwest Airlines(LUV.US$ : Raymond James Upgrades to Strong Buy from Outperform - PT $55 (from $57)
• $MetLife(MET.US$ : Wolfe Research Upgrades to Outperform from Peerperform
• $MGIC Investment(MTG.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $16 (from $15)
• $Snowflake(SNOW.US$ : JPMorgan Upgrades to Overweigh...
• $Funko(FNKO.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $28 (from $25)
• $Southwest Airlines(LUV.US$ : Raymond James Upgrades to Strong Buy from Outperform - PT $55 (from $57)
• $MetLife(MET.US$ : Wolfe Research Upgrades to Outperform from Peerperform
• $MGIC Investment(MTG.US$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $16 (from $15)
• $Snowflake(SNOW.US$ : JPMorgan Upgrades to Overweigh...
17
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg